You are here: Industry Insights > Neratinib

News List

CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies prnasia
December 10, 2021
Today, the final findings of the CONTROL study1 were presented at the 2021 San Antonio Breast Cancer Symposium (SABCS). Results suggest that providing a prophylactic anti-diarrhoea medical treatment...
FDA Approves Neratinib for Metastatic HER2-Positive Breast Cancer americanpharmaceuticalreview
March 05, 2020
The Food and Drug Administration (FDA) approved neratinib (NERLYNX, Puma Biotechnology) in combination with capecitabine for adult patients with advanced or metastatic HER2-positive breast cancer ...
Neratinib defeats the Ras genes notorious for causing cancer europeanpharmaceuticalreview
May 06, 2019
Breast cancer drug neratinib has been found to block the function of the Ras genes which are among the first to be linked to cancer development…
Specialised Therapeutics Asia Initiates Early Access Program For Neratinib prnasia
April 08, 2018
Specialised Therapeutics Asia today announces the initiation of an early access program for neratinib, an extended adjuvant treatment for early-stage HER2-positive (HER2+) breast cancer.
Neratinib prevents Ras genes from causing cancer europeanpharmaceuticalreview
October 12, 2017
Breast cancer drug neratinib has been found to block the function of the Ras genes which are among the first to be linked to cancer development…